癌症中的S100蛋白
S100 Proteins in Cancer
DOI: 10.12677/acm.2024.1492430, PDF,   
作者: 石梦瑶：山东大学齐鲁医院(青岛)检验科，山东 青岛
关键词: S100；癌症；生物标志物；S100； Cancer； Biomarkers
摘要: S100蛋白是一组低分子量的钙结合蛋白，该家族成员在人类基因组中有多种不同的表达形式，它们通过与靶蛋白结合以及调节细胞内信息传递途径等机制，在多种细胞和组织的生理和病理过程中发挥着核心作用。在肿瘤学领域，S100蛋白因其在癌症的发生、发展、转移以及预后中的潜在作用而受到广泛关注。由于S100蛋白在癌症中的重要性，S100家族成员也被证明是有前途的诊断标志物和可能的治疗新靶点，用于癌症的诊断、预后评估和治疗监测。全文就S100蛋白及其在不同癌症类型中的研究进展作一综述，旨在为癌症的综合诊疗提供更全面的参考。
Abstract: S100 proteins are a group of low molecular weight calcium-binding proteins. Members of this family are expressed in various forms in the human genome, and they play a central role in the physiological and pathological processes of many cells and tissues. This is achieved through mechanisms such as binding to target proteins and regulating intracellular information transmission pathways. In the field of oncology, S100 proteins have garnered significant attention due to their potential role in the occurrence, development, metastasis, and prognosis of cancer. Given their substantial impact on cancer, members of the S100 family have shown promise as valuable diagnostic markers and potentially novel therapeutic targets for cancer diagnosis, prognosis assessment, and treatment monitoring. This article provides a review of S100 proteins research progress in different types of cancer with the aim to offer a more comprehensive reference for the comprehensive diagnosis and treatment of cancer.
文章引用：石梦瑶. 癌症中的S100蛋白[J]. 临床医学进展, 2024, 14(9): 71-78. https://doi.org/10.12677/acm.2024.1492430

参考文献

[1] Moore, B.W. (1965) A Soluble Protein Characteristic of the Nervous System. Biochemical and Biophysical Research Communications, 19, 739-744. [Google Scholar] [CrossRef] [PubMed]
[2] Gifford, J.L., Walsh, M.P. and Vogel, H.J. (2007) Structures and Metal-Ion-Binding Properties of the Ca2+-Binding Helix-Loop-Helix EF-Hand Motifs. Biochemical Journal, 405, 199-221. [Google Scholar] [CrossRef] [PubMed]
[3] Santamaria-Kisiel, L., Rintala-Dempsey, A.C. and Shaw, G.S. (2006) Calcium-Dependent and Independent Interactions of the S100 Protein Family. Biochemical Journal, 396, 201-214. [Google Scholar] [CrossRef] [PubMed]
[4] Austermann, J., Spiekermann, C. and Roth, J. (2018) S100 Proteins in Rheumatic Diseases. Nature Reviews Rheumatology, 14, 528-541. [Google Scholar] [CrossRef] [PubMed]
[5] Holzinger, D., Foell, D. and Kessel, C. (2018) The Role of S100 Proteins in the Pathogenesis and Monitoring of Autoinflammatory Diseases. Molecular and Cellular Pediatrics, 5, Article No. 7. [Google Scholar] [CrossRef] [PubMed]
[6] Gonzalez-Martinez, T., Perez-Piñera, P., Díaz-Esnal, B. and Vega, J.A. (2003) S-100 Proteins in the Human Peripheral Nervous System. Microscopy Research and Technique, 60, 633-638. [Google Scholar] [CrossRef] [PubMed]
[7] Harpio, R. and Einarsson, R. (2004) S100 Proteins as Cancer Biomarkers with Focus on S100B in Malignant Melanoma. Clinical Biochemistry, 37, 512-518. [Google Scholar] [CrossRef] [PubMed]
[8] Janka, E.A., Ványai, B., Szabó, I.L., Toka-Farkas, T., Várvölgyi, T., Kapitány, A., et al. (2023) Primary Tumour Category, Site of Metastasis, and Baseline Serum S100B and LDH Are Independent Prognostic Factors for Survival in Metastatic Melanoma Patients Treated with Anti-PD-1. Frontiers in Oncology, 13, Article 1237643. [Google Scholar] [CrossRef] [PubMed]
[9] Ertekin, S.S., Podlipnik, S., Ribero, S., Molina, R., Rios, J., Carrera, C., et al. (2020) Monthly Changes in Serum Levels of S100B Protein as a Predictor of Metastasis Development in High-Risk Melanoma Patients. Journal of the European Academy of Dermatology and Venereology, 34, 1482-1488. [Google Scholar] [CrossRef] [PubMed]
[10] Amaral, T., Seeber, O., Mersi, E., Sanchez, S., Thomas, I., Meiwes, A., et al. (2020) Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma. Cancers, 12, Article 1027. [Google Scholar] [CrossRef] [PubMed]
[11] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
[12] Wang, H., Sun, Z., Zhao, W., et al. (2023) S100A10 Promotes Proliferation and Invasion of Lung Adenocarcinoma Cells by Activating the Akt-mTOR Signaling Pathway. Journal of Southern Medical University, 43, 733-740. [Google Scholar] [CrossRef] [PubMed]
[13] Stewart, R.L., Carpenter, B.L., West, D.S., Knifley, T., Liu, L., Wang, C., et al. (2016) S100A4 Drives Non-Small Cell Lung Cancer Invasion, Associates with Poor Prognosis, and Is Effectively Targeted by the FDA-Approved Anti-Helminthic Agent Niclosamide. Oncotarget, 7, 34630-34642. [Google Scholar] [CrossRef] [PubMed]
[14] Hou, Y., Zhang, J., Guo, J. and Chen, H. (2021) Clinical Significance of Serum S100A10 in Lung Cancer. Journal of International Medical Research, 49, Article 030006052110496. [Google Scholar] [CrossRef] [PubMed]
[15] Park, W., Gray, J.M., Holewinski, R.J., Andresson, T., So, J.Y., Carmona-Rivera, C., et al. (2023) Apoptosis-Induced Nuclear Expulsion in Tumor Cells Drives S100a4-Mediated Metastatic Outgrowth through the RAGE Pathway. Nature Cancer, 4, 419-435. [Google Scholar] [CrossRef] [PubMed]
[16] Sumardika, I.W., Chen, Y., Tomonobu, N., Kinoshita, R., Ruma, I.M.W., Sato, H., et al. (2019) Neuroplastin-β Mediates S100a8/a9-Induced Lung Cancer Disseminative Progression. Molecular Carcinogenesis, 58, 980-995. [Google Scholar] [CrossRef] [PubMed]
[17] Hua, T., Liu, S., Xin, X., Cai, L., Shi, R., Chi, S., et al. (2016) S100A4 Promotes Endometrial Cancer Progress through Epithelial-Mesenchymal Transition Regulation. Oncology Reports, 35, 3419-3426. [Google Scholar] [CrossRef] [PubMed]
[18] Bulk, E., Sargin, B., Krug, U., Hascher, A., Jun, Y., Knop, M., et al. (2008) S100A2 Induces Metastasis in Non-Small Cell Lung Cancer. Clinical Cancer Research, 15, 22-29. [Google Scholar] [CrossRef] [PubMed]
[19] Gianni, M., Terao, M., Kurosaki, M., Paroni, G., Brunelli, L., Pastorelli, R., et al. (2022) Correction: S100A3 a Partner Protein Regulating the Stability/activity of Rarα and Pml-Rarα in Cellular Models of Breast/Lung Cancer and Acute Myeloid Leukemia. Oncogene, 42, 254-258. [Google Scholar] [CrossRef] [PubMed]
[20] Mahmood, M.Q., Ward, C., Muller, H.K., Sohal, S.S. and Walters, E.H. (2017) Epithelial Mesenchymal Transition (EMT) and Non-Small Cell Lung Cancer (NSCLC): A Mutual Association with Airway Disease. Medical Oncology, 34, Article No. 45. [Google Scholar] [CrossRef] [PubMed]
[21] Gianni, M., Terao, M., Kurosaki, M., Paroni, G., Brunelli, L., Pastorelli, R., et al. (2018) S100A3 a Partner Protein Regulating the Stability/Activity of RARα and PML-RARα in Cellular Models of Breast/Lung Cancer and Acute Myeloid Leukemia. Oncogene, 38, 2482-2500. [Google Scholar] [CrossRef] [PubMed]
[22] Orre, L.M., Panizza, E., Kaminskyy, V.O., Vernet, E., Gräslund, T., Zhivotovsky, B., et al. (2013) S100A4 Interacts with P53 in the Nucleus and Promotes P53 Degradation. Oncogene, 32, 5531-5540. [Google Scholar] [CrossRef] [PubMed]
[23] Arumugam, T. and Logsdon, C.D. (2010) S100P: A Novel Therapeutic Target for Cancer. Amino Acids, 41, 893-899. [Google Scholar] [CrossRef] [PubMed]
[24] He, X., Xu, X., Khan, A.Q. and Ling, W. (2017) High Expression of S100A6 Predicts Unfavorable Prognosis of Lung Squamous Cell Cancer. Medical Science Monitor, 23, 5011-5017. [Google Scholar] [CrossRef] [PubMed]
[25] Sung, M. and Simon, R. (2004) Candidate Epitope Identification Using Peptide Property Models: Application to Cancer Immunotherapy. Methods, 34, 460-467. [Google Scholar] [CrossRef] [PubMed]
[26] Heinecke, J.L., Ridnour, L.A., Cheng, R.Y.S., Switzer, C.H., Lizardo, M.M., Khanna, C., et al. (2014) Tumor Microenvironment-Based Feed-Forward Regulation of NOS2 in Breast Cancer Progression. Proceedings of the National Academy of Sciences, 111, 6323-6328. [Google Scholar] [CrossRef] [PubMed]
[27] Huang, P. and Xue, J. (2020) Long Non‑coding RNA FOXD2‑AS1 Regulates the Tumorigenesis and Progression of Breast Cancer via the S100 Calcium Binding Protein A1/Hippo Signaling Pathway. International Journal of Molecular Medicine, 46, 1477-1489. [Google Scholar] [CrossRef] [PubMed]
[28] Liu, A., Li, Y., Lu, S., Cai, C., Zou, F. and Meng, X. (2023) Stanniocalcin 1 Promotes Lung Metastasis of Breast Cancer by Enhancing EGFR-ERK-S100A4 Signaling. Cell Death & Disease, 14, Article No. 395. [Google Scholar] [CrossRef] [PubMed]
[29] Zhang, S., Wang, Z., Liu, W., Lei, R., Shan, J., Li, L., et al. (2017) Distinct Prognostic Values of S100 mRNA Expression in Breast Cancer. Scientific Reports, 7, Article No. 39786. [Google Scholar] [CrossRef] [PubMed]
[30] Aka, J.A. and Lin, S. (2012) Correction: Comparison of Functional Proteomic Analyses of Human Breast Cancer Cell Lines T47D and MCF7. PLOS ONE, 7, e31532. [Google Scholar] [CrossRef] 
[31] Cong, Y., Cui, Y., Wang, S., Jiang, L., Cao, J., Zhu, S., et al. (2020) Calcium-Binding Protein S100P Promotes Tumor Progression but Enhances Chemosensitivity in Breast Cancer. Frontiers in Oncology, 10, Article 5660302. [Google Scholar] [CrossRef] [PubMed]
[32] Lee, S., Cho, Y., Li, Y., et al. (2024) Cancer-Cell Derived S100A11 Promotes Macrophage Recruitment in ER+ Breast Cancer.
[33] Nava, M., Dutta, P., Zemke, N.R., Farias-Eisner, R., Vadgama, J.V. and Wu, Y. (2019) Transcriptomic and Chip-Sequence Interrogation of EGFR Signaling in HER2+ Breast Cancer Cells Reveals a Dynamic Chromatin Landscape and S100 Genes as Targets. BMC Medical Genomics, 12, Article No. 32. [Google Scholar] [CrossRef] [PubMed]
[34] Wang, Y., Li, S., Hu, M., Yang, Y., McCabe, E., Zhang, L., et al. (2024) Universal STING Mimic Boosts Antitumour Immunity via Preferential Activation of Tumour Control Signalling Pathways. Nature Nanotechnology, 19, 856-866. [Google Scholar] [CrossRef] [PubMed]
[35] Chen, L., Shu, P., Zhang, X., Ye, S., Tian, L., Shen, S., et al. (2024) S100a8-Mediated Inflammatory Signaling Drives Colorectal Cancer Progression via the CXCL5/CXCR2 Axis. Journal of Cancer, 15, 3452-3465. [Google Scholar] [CrossRef] [PubMed]
[36] Li, S., Zhang, J., Qian, S., Wu, X., Sun, L., Ling, T., et al. (2021) S100A8 Promotes Epithelial-Mesenchymal Transition and Metastasis under TGF-β/USF2 Axis in Colorectal Cancer. Cancer Communications, 41, 154-170. [Google Scholar] [CrossRef] [PubMed]
[37] Fukuda, Y., Tanaka, Y., Eto, K., Ukai, N., Sonobe, S., Takahashi, H., et al. (2022) S100-Stained Perineural Invasion Is Associated with Worse Prognosis in Stage I/II Colorectal Cancer: Its Possible Association with Immunosuppression in the Tumor. Pathology International, 72, 117-127. [Google Scholar] [CrossRef] [PubMed]
[38] Wang, H., Duan, L., Zou, Z., Li, H., Yuan, S., Chen, X., et al. (2022) Activation of the PI3k/Akt/mTOR/p70S6K Pathway Is Involved in S100A4-Induced Viability and Migration in Colorectal Cancer Cells: Erratum. International Journal of Medical Sciences, 19, 352-352. [Google Scholar] [CrossRef] [PubMed]
[39] Hsieh, Y., Cheng, Y., Wei, P. and Yang, P. (2022) Repurposing of Ingenol Mebutate for Treating Human Colorectal Cancer by Targeting S100 Calcium-Binding Protein A4 (S100A4). Toxicology and Applied Pharmacology, 449, Article 116134. [Google Scholar] [CrossRef] [PubMed]
[40] Cho, E., Mun, S., Kim, H.K., Ham, Y.S., Gil, W.J. and Yang, C. (2023) Colon-Targeted S100A8/A9-Specific Peptide Systems Ameliorate Colitis and Colitis-Associated Colorectal Cancer in Mouse Models. Acta Pharmacologica Sinica, 45, 581-593. [Google Scholar] [CrossRef] [PubMed]
[41] Hermani, A., Deservi, B., Medunjanin, S., Tessier, P. and Mayer, D. (2006) S100A8 and S100A9 Activate MAP Kinase and NF-Κb Signaling Pathways and Trigger Translocation of RAGE in Human Prostate Cancer Cells. Experimental Cell Research, 312, 184-197. [Google Scholar] [CrossRef] [PubMed]
[42] Palanissami, G. and Paul, S.F.D. (2023) Ages and RAGE: Metabolic and Molecular Signatures of the Glycation-Inflammation Axis in Malignant or Metastatic Cancers. Exploration of Targeted Anti-Tumor Therapy, 4, 812-849. [Google Scholar] [CrossRef] [PubMed]
[43] Zhu, W., Xue, Y., Liang, C., Zhang, R., Zhang, Z., Li, H., et al. (2016) S100A16 Promotes Cell Proliferation and Metastasis via AKT and ERK Cell Signaling Pathways in Human Prostate Cancer. Tumor Biology, 37, 12241-12250. [Google Scholar] [CrossRef] [PubMed]
[44] Lv, Z., Li, W. and Wei, X. (2020) S100A9 Promotes Prostate Cancer Cell Invasion by Activating TLR4/NF-Κb/Integrin Β1/FAK Signaling. OncoTargets and Therapy, 13, 6443-6452. [Google Scholar] [CrossRef] [PubMed]
[45] Vogl, T., Gharibyan, A.L. and Morozova-Roche, L.A. (2012) Pro-Inflammatory S100A8 and S100A9 Proteins: Self-Assembly into Multifunctional Native and Amyloid Complexes. International Journal of Molecular Sciences, 13, 2893-2917. [Google Scholar] [CrossRef] [PubMed]
[46] Papaevangelou, E., Esteves, A.M., Dasgupta, P. and Galustian, C. (2023) Cyto-IL-15 Synergizes with the STING Agonist ADU-S100 to Eliminate Prostate Tumors and Confer Durable Immunity in Mouse Models. Frontiers in Immunology, 14, Article 1196829. [Google Scholar] [CrossRef] [PubMed]
[47] Han, D., Guo, C., Cheng, H., Lu, J., Hou, Z., Zhang, X., et al. (2024) Downregulation of S100A11 Promotes T Cell Infiltration by Regulating Cancer-Associated Fibroblasts in Prostate Cancer. International Immunopharmacology, 128, Article 111323. [Google Scholar] [CrossRef] [PubMed]
[48] Kim, B., Jung, S., Kim, H., Kwon, J., Song, M., Kim, M.K., et al. (2021) The Role of S100A4 for Bone Metastasis in Prostate Cancer Cells. BMC Cancer, 21, Article No. 137. [Google Scholar] [CrossRef] [PubMed]
[49] Ruma, I.M.W., Kinoshita, R., Tomonobu, N., Inoue, Y., Kondo, E., Yamauchi, A., et al. (2018) Embigin Promotes Prostate Cancer Progression by S100A4-Dependent and Independent Mechanisms. Cancers, 10, Article 239. [Google Scholar] [CrossRef] [PubMed]
[50] Liu, J., Li, X., Dong, G., Zhang, H., Chen, D., Du, J., et al. (2008) In Silico Analysis and Verification of S100 Gene Expression in Gastric Cancer. BMC Cancer, 8, Article No. 261. [Google Scholar] [CrossRef] [PubMed]
[51] Koh, S.A. and Lee, K.H. (2018) HGF-Mediated S100A11 Over-Expression Enhances Proliferation and Invasion of Gastric Cancer. American Journal of Translational Research, 10, 3385-3394.
[52] Cui, Y., Li, L., Li, Z., Yin, J., Lane, J., Ji, J., et al. (2021) Dual Effects of Targeting S100A11 on Suppressing Cellular Metastatic Properties and Sensitizing Drug Response in Gastric Cancer. Cancer Cell International, 21, Article No. 243. [Google Scholar] [CrossRef] [PubMed]
[53] Li, Y., Li, X., Li, L., Zhou, R., Sikong, Y., Gu, X., et al. (2020) S100A10 Accelerates Aerobic Glycolysis and Malignant Growth by Activating mTOR-Signaling Pathway in Gastric Cancer. Frontiers in Cell and Developmental Biology, 8, Article 559486. [Google Scholar] [CrossRef] [PubMed]
[54] Feng, L., Zheng, X., Zhou, L., Fu, B., Yu, Y., Lu, S., et al. (2011) Correlation between Expression of S100A4 and VEGF-C, and Lymph Node Metastasis and Prognosis in Gastric Carcinoma. Journal of International Medical Research, 39, 1333-1343. [Google Scholar] [CrossRef] [PubMed]
[55] Wang, C., Luo, J., Rong, J., He, S., Zhang, L. and Zheng, F. (2019) Distinct Prognostic Roles of S100 mRNA Expression in Gastric Cancer. Pathology—Research and Practice, 215, 127-136. [Google Scholar] [CrossRef] [PubMed]

为你推荐